AbbVie's (ABBV) three-drug combo for Hepatitis C cured 96.2-96.3% of patients in two Phase III trials, known as Sapphire-I and Sapphire-II.
The subjects in Sapphire II included those who hadn't responded well to previous treatment.
The regimen includes an Enanta (ENTA) inhibitor. (PR)
See more on Hepatitis C drug studies.